Abbrev.
|
Definition
|
ACC |
adenoid cystic carcinoma |
AML |
acute myelocytic leukemia |
Bcl-2 |
B-cell lymphoma 2 |
Btz |
bortezomib |
CDK |
cyclin-dependent kinase |
CML |
chronic myelogenous leukemia |
CPT |
camptothecin |
DAG |
diacylglycerol |
DN |
dominant-negative |
EGFR |
epidermal growth factor receptor |
ERK |
extracellular signal-regulated kinase |
GBM |
glioblastoma multiforme |
HSC |
hematopoietic stem cells |
IFN |
Interferon-α |
IM |
imatinib mesylate |
JNK |
c-Jun N-terminal kinase |
LSC |
leukemia stem cells |
MAPK |
mitogen-activated protein kinase |
Mcl-1 |
myeloid cell leukemia 1 |
mTOR |
mechanistic target of rapamycin |
MTT |
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
NF-κB |
nuclear factor-κB |
NHEK |
normal human epidermal keratinocytes |
NHF |
normal human fibroblasts |
NHK |
normal human keratinocytes |
ODN |
oligonucleotide |
PKC |
protein kinase C |
SASP |
senescence-associated secretory phenotype |
SRF |
Sorafenib |
TNF |
tumor necrosis factor-α |
TGase 1 |
transglutaminase 1 |
TPA |
12-O-tetradecanoylphorbol-13-acetate |
TRAIL |
TNF-related apoptosis-inducing ligand |
WT |
wild-type |